Wedbush reissued their outperform rating on shares of Prevail Therapeutics (NASDAQ:PRVL) in a research note released on Thursday morning, The Fly reports. They currently have a $20.00 target price on the stock, down from their previous target price of $25.00.

A number of other brokerages have also weighed in on PRVL. Morgan Stanley started coverage on shares of Prevail Therapeutics in a research note on Monday, July 15th. They issued an overweight rating and a $20.00 price target on the stock. Cowen started coverage on shares of Prevail Therapeutics in a research note on Monday, July 15th. They issued an outperform rating on the stock. Finally, Bank of America started coverage on shares of Prevail Therapeutics in a research note on Monday, July 15th. They issued a buy rating and a $15.00 price target on the stock.

Shares of PRVL opened at $10.90 on Thursday. Prevail Therapeutics has a twelve month low of $7.41 and a twelve month high of $16.90. The firm has a 50 day moving average of $11.23.

Prevail Therapeutics (NASDAQ:PRVL) last announced its quarterly earnings results on Wednesday, August 14th. The company reported ($0.58) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($1.24) by $0.66. On average, equities research analysts expect that Prevail Therapeutics will post -2.51 EPS for the current year.

In related news, Director Carl L. Gordon purchased 882,352 shares of the business’s stock in a transaction on Monday, June 24th. The shares were purchased at an average price of $17.00 per share, with a total value of $14,999,984.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Hedge funds have recently made changes to their positions in the company. Blackstone Group Inc bought a new stake in shares of Prevail Therapeutics in the second quarter worth $66,000. EcoR1 Capital LLC bought a new stake in shares of Prevail Therapeutics in the second quarter worth $31,582,000. Marshall Wace North America L.P. bought a new stake in shares of Prevail Therapeutics in the second quarter worth $520,000. Vanguard Group Inc. bought a new stake in shares of Prevail Therapeutics in the second quarter worth $1,015,000. Finally, DRW Securities LLC bought a new stake in shares of Prevail Therapeutics in the second quarter worth $652,000. 0.17% of the stock is currently owned by institutional investors and hedge funds.

About Prevail Therapeutics

Prevail Therapeutics Inc, a gene therapy company, focuses on developing and commercializing disease-modifying AAV-based gene therapies for patients with devastating neurodegenerative diseases. The company's lead product candidate is PR001 for the treatment of Parkinson's disease with GBA1 mutation and neuronopathic Gaucher disease.

Featured Article: Municipal Bonds

The Fly

Receive News & Ratings for Prevail Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prevail Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.